Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
W. Pollahne, T. Grieser, M. Pfeifer, H.W. Minne.
Diagnóstico y diagnóstico diferencial de las osteoporosis primaria y secundaria (1.a ed.). J & C Ed.
Médicas,, 5 (1998),
[2.]
Consensus development conference, International Osteoporosis Fundation.
Berlín, (1998),
[3.]
D.M. Black, S.R. Cummings, D.B. Karpf, J.A. Canley, D.E. Thompson, M.C. Nevittet, et al.
for the Fracture Intervention Trial Research Group. Randomized trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures.
Lancet, 348 (1996), pp. 1535
[4.]
B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, H.K. Genant, et al.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifen.
JAMA, 282 (1999), pp. 637-645
[5.]
S.L. Silverman, C. Chesnut, K. Adriano.
Salmon calcitonin nasal spray reduces risk of vertebral fractures in established osteoporosis and has continuous efficacy with prolonged treatment: accrued 5 year worldwide data of the proof study.
Bone, 23 (1998), pp. 174
[6.]
IOF.
Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost effectiveness analysis.
Osteop Int, (1998), pp. 7-80
[7.]
T. Storm, G. Thamsborg, T. Stemiche, H.K. Genant, O.H. Sorensen.
Effect of intermittent cyclical etidronate therapyon bone mass and fracture rate in women with postmenopausal osteoporosis.
N Engl J Med, 323 (1990), pp. 1265-1271
[8.]
N.B. Watts, S.T. Harris, H.K. Genant, R.A. Wasnich, P.D. Miller, R.D. Jackson, et al.
Intermitent cyclical etidronate treatment of postmenopausal osteoporosis.
N Engl J Med, 323 (1990), pp. 73-79
Copyright © 2000. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
